NCT03505554 2023-08-07
CRU3
University of Milano Bicocca
Phase 2 Unknown
Clinical Trials
5 trialsNCT03612154 2022-04-06
Study of Lorlatinib in ROS1 Rearranged NSCLC
National Cancer Center, Korea
Phase 2 Unknown
NCT03439215 2021-07-19
PFROST
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown
NCT02927340 2021-03-09
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Massachusetts General Hospital
Phase 2 Unknown